BCAB
BioAtla, Inc.
Next earnings Aug 5, 2026 · consensus $-0.17 EPS
Last earnings +4.5% on 2026-03-31
$3.83
▲ +4.08%$3.83▼ -81.41%
over 1Y
L $3.31EODHDH $61.00
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+4.1%
1W+5.8%
1M+8.5%
3M-50.3%
YTD-85.7%
1Y-81.4%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 7 analysts
Buy
Conservative balance sheet (liabilities/equity -1.38x); but unprofitable (net margin -19869.0%).
Revenue (FY2021) $300K · FY2021
BioAtla, Inc. shows $300K in FY2021 revenue, a -19869.0% net margin.
Supporting the case: conservative balance sheet (liabilities/equity -1.38x).
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $300K | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$96.4M | -$108M | -$130M | -$73.9M | -$59.3M |
| Net income | -$95.4M | -$106M | -$123M | -$69.8M | -$59.6M |
| Diluted EPS | -$2.76 | -$2.74 | -$2.58 | -$1.44 | -$1.01 |
| Net margin | -31800.7% | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$236M
EV / EBITDA—
EV / Sales786.5
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-24.5%
FCF yield—
Quality & risk
ROIC (est.)—
Free cash flow—
Total debt—
Net cash$7.12M
Altman Z-Score-67.67 distress
Piotroski F-Score1/6
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+9.2%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — restated periodic report (2026-04-29). Worth a closer look.
Recent filings
all on EDGAR ↗4Period ending 2026-03-112026-06-05open ↗4Period ending 2026-03-122026-06-05open ↗4Period ending 2026-03-112026-06-05open ↗ARSPeriod ending 2025-12-312026-06-03open ↗DEFA14AFiling2026-06-03open ↗DEF 14APeriod ending 2026-06-032026-06-03open ↗10-QPeriod ending 2026-03-312026-05-15open ↗10-K/APeriod ending 2025-12-312026-04-29open ↗8-KPeriod ending 2026-04-022026-04-02open ↗S-8Filing2026-03-31open ↗10-KPeriod ending 2025-12-312026-03-31open ↗8-KPeriod ending 2026-03-312026-03-31open ↗
Frequently asked
- Is BioAtla, Inc. (BCAB) a buy?
- BCAB currently carries a Avoid rating with 3/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity -1.38x); but unprofitable (net margin -19869.0%).
- What is BioAtla, Inc.'s quality score?
- BCAB scores 33.52941176470588/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001826892, latest 10-Q filed 2026-05-15) · EODHD · as of 6/30/2026, 9:56:01 AM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.